Fed. Circ. Kills Patent Fight After Momenta Ditches Biosimilar
Momenta Pharmaceuticals Inc. can't challenge a patent for Bristol-Myers Squibb Co.'s rheumatoid arthritis drug Orencia because Momenta has stopped developing a biosimilar version of the blockbuster product, the Federal Circuit ruled...To view the full article, register now.
Already a subscriber? Click here to view full article